A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer

被引：0
|
作者：
Stockton, Shannon
Soares, Heloisa P.
Dayyani, Farshid
Saeed, Anwaar
Kim, Edward S.
Jin, Ning
Yacoub, George Hosni
Whisenant, Jennifer
Ayers, G. Dan
Gore, Steven
Das, Satya
Berlin, Jordan
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Utah, Hunstman Canc Hosp, Salt Lake City, UT USA
[3] Univ Calif Irvine, Div Hematol Oncol, Dept Med, Orange, CA USA
[4] UPMC, Dept Med, Div Hematol & Oncol, UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[5] City Hope Natl Med Ctr, Irvine, CA USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[7] Wake Forest Univ, Dept Gen Internal Med, Winston Salem, NC USA
[8] NCI, Rockville, MD USA
[9] Astra Zeneca, Gaithersburg, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4044
引用
收藏
页数：1
相关论文
共 50 条
  • [31] APATINIB COMBINED WITH IRINOTECAN AND TEMOZOLOMIDE IN CHILDREN AND ADULT WITH REFRACTORY/PROGRESSIVE/RELAPSED NEUROBLASTOMA (APTN-01): A PHASE 2, SINGLE-ARM, PROSPECTIVE STUDY
    Wang, Juan
    Lu, Suying
    Sun, Feifei
    Zhen, Zijun
    Que, Yi
    Zhu, Jia
    Huang, Junting
    Zhang, Yizhuo
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S90 - S90
  • [32] A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer
    Yuan, Guangwen
    Li, Zhiping
    Ye, Feng
    Zhang, Bingzhong
    Shen, Lin
    Zhang, Yan-Qiao
    Yu, Xianjun
    Cheng, Ying
    Liu, Baorui
    Wang, Jianliu
    Chen, Xiaojun
    Zhou, Jinghong
    Shi, Haiyan
    Tan, Panfeng
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    Wu, Lingying
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction (GEI).
    Ko, A. H.
    Tabernero, J.
    Garcia De Paredes, M.
    Rivera, F.
    Schnell, F. M.
    Baker, J. S.
    Phan, A. T.
    Alsina, M.
    Patel, K.
    Ajani, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] FINAL RESULTS AND BIOMARKER CORRELATION OF A PHASE II STUDY OF THE MTOR INHIBITOR EVEROLIMUS IN PATIENTS WITH PRE-TREATED METASTATIC ESOPHAGUS, GASTRO-ESOPHAGEAL JUNCTION AND GASTRIC ADENOCARCINOMA
    Zev, Wainberg
    Ravi, Patel
    David, Park
    Andre, Liem
    Lisa, Yonemoto
    Brian, DiCarlo
    Wang He-Jing
    Diego, Martinez
    Hecht, J.
    ANNALS OF ONCOLOGY, 2014, 25 : 87 - 87
  • [35] Phase 2 Study of Capecitabine and Irinotecan Combination Chemotherapy (Modified XELIRI Regimen) in Patients With Advanced Gastric Cancer
    Luo, Hui-yan
    Wang, Zhi-qiang
    Wang, Feng-hua
    Qiu, Miao-zhen
    Teng, Kai-yuan
    Ruan, Dan-yun
    He, You-jian
    Li, Yu-hong
    Xu, Rui-hua
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (06): : 555 - 560
  • [36] Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study
    Zhichao Jiang
    Aiping Zhou
    Yongkun Sun
    Wen Zhang
    BMC Cancer, 22
  • [37] Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study
    Jiang, Zhichao
    Zhou, Aiping
    Sun, Yongkun
    Zhang, Wen
    BMC CANCER, 2022, 22 (01)
  • [38] Afatinib in combination with cisplatin and 5-fluorouracil (5-FU) as first line treatment in inoperable gastric and gastro-esophageal junction (GEJ) cancer: A phase II study by the Hellenic Cooperative Oncology Group
    Makatsoris, T.
    Samantas, E.
    Manousou, K.
    Karavasilis, V.
    Aravantinos, G.
    Tryfonopoulos, D.
    Psyrri, A.
    Pectasides, D. G.
    Pazarli, E.
    Petraki, C.
    Tsipoura, A.
    Kaklamanos, I. G.
    Fountzilas, G.
    Pentheroudakis, G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II multicenter single-arm study and exploratory biomarker analysis
    Xu, Ting
    Wang, Xicheng
    Xin, Ying
    Wang, Zhenghang
    Wang, Yakun
    Qi, Changsong
    Liu, Dan
    Li, Yanyan
    Gong, Jifang
    Li, Jian
    Huang, Depei
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [40] Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer(GC/GEJC): Initial findings of a single-arm phase II trial
    Ding, Xuewei
    Li, Bin
    Xue, Qiang
    Cai, Mingzhi
    Cui, Jingli
    Wang, Baogui
    Ke, Bin
    Zhang, Rupeng
    Liang, Han
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345